In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…
A Phase 3 clinical trial for Non-Germinal Center Diffuse Large B-Cell Lymphoma in patients where it was previously untreated have just announced they are still recruiting participants. The trial is…
According to a story from USA Today, Mark Hoppus, bass player for the iconic pop-punk band Blink-182, was recently diagnosed with a rare cancer: diffuse large B-cell lymphoma. His cancer…
Clinical trials can be crucial in determining potential treatment options for a variety of conditions. According to Pharma Biz, biopharmaceutical company Nordic Nanovector ("Nordic") recently shared promising data from the…
The European Hematology Association (EHA) held its 2021 Virtual Congress from June 9-17, 2021, though the insights will be available until mid-August 2021. During the Congress, researchers discussed new…
For many patients with diffuse large B-cell lymphoma (DLBCL), one first-line treatment is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, even aggressive chemotherapy is not always enough for patients…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
